According to the experimental results, the tumors in the cisplatin-resistant group were significantly larger compared to those in the cisplatin-sensitive group, while tumor growth was markedly slowed in the TFAP2C-silenced cisplatin-resistant group (Fig. 8, A–C). The gene discussed is TFAP2C; the disease is neoplasm.